Portfolio

AbbVie Ventures is focused on early-stage opportunities in oncology, immunology, neuroscience, eye care, and aesthetics.

Active portfolio

Accent Therapeutics is leading the translation of RNA-modifying protein(RMP)biology into promising new precision therapies for cancer.

Aquinnah Pharmaceuticals is developing small molecule therapeutics targeting pathologic proteins associated with persistent stress granules for the treatment of neurodegenerative disease.

Artios Pharma is developing cancer treatments that target DNA Damage Response pathways to selectively kill cancer cells.

Capsida Therapeutics is creating a new class of targeted gene therapies for both CNS and non-CNS disorders.

Cephagenix is exploring a novel MoA for the treatment of migraines.

Dimericon Therapeutics is exploring cross-linked helix dimers as therapeutics for small molecule development.

DISCO Pharmaceuticals is developing novel mass spectrometry methods to decode the cancer cell surface.

DG Medicines is employing a novel drug discovery platform to identify therapeutics for targeted protein degradation.

EndLyz Therapeutics is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias.

Enthera is developing first-in-class therapeutics for severe autoimmune disorders.

EvolveImmune Therapeutics is developing a proprietary multi-specific T-cell engager platform with costimulation.

FireCyte is an emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye.

Gate Neurosciences is using precision medicine to pioneer a new class of rapid-acting therapies targeting synaptic health.

Kojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology.

Light Horse Therapeutics is developing novel CRISPR-based functional site-dependency maps with advanced drug discovery capabilities as a platform technology with broad therapeutic relevance.

Mozart Therapeutics is orchestrating a novel regulatory CD8 T cell network to discover and develop disease modifying therapies that restore immune balance in autoimmune and inflammatory diseases.

Nitrase Therapeutics is developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases.

Oisin Biotechnologies is advancing a pipeline of therapies for age-related diseases: eliminating unwanted fat cells and building muscle mass.

Palleon Pharmaceuticals is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.

Parvus Therapeutics is developing Navacim platform: presentation of peptide-MHCs to T cells to induce Treg differentiation.

Portera Therapeutics is developing small molecule enhancers of the proteasome.

Quanta Therapeutics is pioneering allosteric modulation to control RAS signaling for inhibition of the full scope of RAS-driven cancer types.

ReAx Biotechnologies is developing activity-dependent protein ligation technology for quantitative in-cell profiling.

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human disease.

Sionna Therapeutics (NASDAQ: SION) is advancing a cystic fibrosis-focused pipeline featuring novel mechanisms of action with the potential to redefine standard of care.

SNC Therapeutics is developing a synthetic drug carrier platform for subcutaneous nanotherapy.

Third Arc Bio is developing multifunctional antibodies optimized for T cell engagement across solid tumors and immunology.

Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.

Umoja Biopharma is pioneering the future of immunotherapy by reprogramming T cells in vivo.

XenImmune Therapeutics is applying the biology of organ transplant hyperacute rejection to fight cancer.

Xilio Therapeutics (NASDAQ: XLO) is developing a clinically-validated platform technology for tumor-activated masked biologics, including T cell engagers.

Immunology Stealth NewCo is harnessing natural mechanisms for tolerance induction to transform outcomes in autoimmunity.

Immunology Stealth NewCo is developing a novel antigen-agnostic approach for rheumatoid arthritis and other inflammatory diseases.

Genetic Medicine Stealth Newco's mission is to develop medicines enabled by extrahepatic cell-specific delivery of RNAs.

Immunology Stealth NewCo identifying dysfunctional signaling axes in gastrointestinal disease based on human biology drugged via an engineered-bug-as-drug approach.